JP2025502861A - 抗FXI/FXIa抗体を含む医薬組成物及びその使用 - Google Patents
抗FXI/FXIa抗体を含む医薬組成物及びその使用 Download PDFInfo
- Publication number
- JP2025502861A JP2025502861A JP2024540670A JP2024540670A JP2025502861A JP 2025502861 A JP2025502861 A JP 2025502861A JP 2024540670 A JP2024540670 A JP 2024540670A JP 2024540670 A JP2024540670 A JP 2024540670A JP 2025502861 A JP2025502861 A JP 2025502861A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- fxi
- sucrose
- histidine
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210006206.X | 2022-01-05 | ||
| CN202210006206 | 2022-01-05 | ||
| CN202210053441 | 2022-01-18 | ||
| CN202210053441.2 | 2022-01-18 | ||
| PCT/CN2023/070573 WO2023131213A1 (zh) | 2022-01-05 | 2023-01-05 | 一种包含抗FXI/FXIa抗体的药物组合物及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025502861A true JP2025502861A (ja) | 2025-01-28 |
| JP2025502861A5 JP2025502861A5 (cg-RX-API-DMAC10.html) | 2026-01-15 |
Family
ID=87073189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024540670A Pending JP2025502861A (ja) | 2022-01-05 | 2023-01-05 | 抗FXI/FXIa抗体を含む医薬組成物及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250179213A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4461749A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025502861A (cg-RX-API-DMAC10.html) |
| CN (1) | CN118382643A (cg-RX-API-DMAC10.html) |
| TW (1) | TW202333789A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023131213A1 (cg-RX-API-DMAC10.html) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11066481B2 (en) * | 2015-07-23 | 2021-07-20 | The Regents Of The University Of California | Antibodies to coagulation factor XIa and uses thereof |
| TW201802121A (zh) * | 2016-05-25 | 2018-01-16 | 諾華公司 | 抗因子XI/XIa抗體之逆轉結合劑及其用途 |
| PT3570882T (pt) * | 2017-01-19 | 2022-01-11 | Bayer Pharma AG | Nova formulação estável para anticorpos fxia |
| RU2766590C2 (ru) * | 2017-05-16 | 2022-03-15 | Цзянсу Хэнжуй Медисин Ко., Лтд. | Фармацевтическая композиция на основе антитела к pd-l1 и ее применение |
| EP3713965A1 (en) * | 2017-11-22 | 2020-09-30 | Novartis AG | Reversal binding agents for anti-factor xi/xia antibodies and uses thereof |
| WO2020008022A1 (en) * | 2018-07-05 | 2020-01-09 | Bayer Aktiengesellschaft | METHOD FOR THE PRODUCTION OF FREEZE-DRIED PELLETS COMPRISING AN ANTI-COAGULATION FACTOR XIa (FXIa) ANTIBODY |
| CN110732023B (zh) * | 2018-07-18 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | 一种her2抗体药物组合物及其用途 |
| US12703762B2 (en) * | 2018-12-18 | 2026-08-11 | Novartis Ag | Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof |
| EP3957652A4 (en) * | 2019-04-16 | 2023-06-21 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Anti-fxi/fxia antibody and use thereof |
| JP2023507795A (ja) * | 2019-12-20 | 2023-02-27 | アントス セラピューティクス, インコーポレイテッド | 第XI/XIa因子抗体の医薬製剤および投薬レジメン |
| BR112022026533A2 (pt) * | 2020-07-02 | 2023-01-17 | Beijing Tuo Jie Biopharmaceutical Co Ltd | Anticorpo anti-fxi/fxia, fragmento de ligação do mesmo, e antígenos e uso farmacêutico do mesmo |
-
2023
- 2023-01-05 EP EP23737076.2A patent/EP4461749A4/en active Pending
- 2023-01-05 TW TW112100422A patent/TW202333789A/zh unknown
- 2023-01-05 JP JP2024540670A patent/JP2025502861A/ja active Pending
- 2023-01-05 WO PCT/CN2023/070573 patent/WO2023131213A1/zh not_active Ceased
- 2023-01-05 US US18/726,599 patent/US20250179213A1/en active Pending
- 2023-01-05 CN CN202380015149.4A patent/CN118382643A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN118382643A (zh) | 2024-07-23 |
| WO2023131213A1 (zh) | 2023-07-13 |
| EP4461749A4 (en) | 2025-03-26 |
| US20250179213A1 (en) | 2025-06-05 |
| EP4461749A1 (en) | 2024-11-13 |
| TW202333789A (zh) | 2023-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110198739B (zh) | 一种pd-l1抗体药物组合物及其用途 | |
| CN110538321B (zh) | 一种cd47抗体药物组合物及其用途 | |
| JP7807081B2 (ja) | 抗FXI/FXIa抗体、その抗原結合断片と医薬用途 | |
| JP2026048838A (ja) | 高濃度抗c5抗体配合物 | |
| US20220031842A1 (en) | Lag-3 antibody pharmaceutical composition and use thereof | |
| KR102962504B1 (ko) | Il-5에 대한 항체를 함유하는 약학적 조성물 및 이의 용도 | |
| US20210261663A1 (en) | Anti-tim3 antibody pharmaceutical composition and use thereof | |
| JP2023515423A (ja) | 抗il-4r抗体医薬組成物及びその使用 | |
| KR20230044448A (ko) | 항-pd-1 항체 약학적 조성물 및 이의 용도 | |
| JP2023109987A (ja) | 抗ヒトgpvi抗体を用いた血小板凝集の阻害 | |
| CN111375059B (zh) | 一种抗gitr抗体药物组合物及其用途 | |
| KR20240035835A (ko) | 항-angptl3 항체 또는 이의 항원 결합 단편의 약학적 조성물 및 이의 응용 | |
| EP4257603A1 (en) | Pharmaceutical composition comprising anti-connective tissue growth factor antibody | |
| CN112839961B (zh) | 一种cd40抗体药物组合物及其用途 | |
| US20250179213A1 (en) | Pharmaceutical composition comprising anti-fxi/fxia antibody and use thereof | |
| CN120437287A (zh) | 一种包含特异性结合gucy2c和cd3的双特异性抗体的药物组合物 | |
| EA052061B1 (ru) | Фармацевтическая композиция антитела против angptl3 или его антигенсвязывающего фрагмента и ее применение | |
| HK40047597A (en) | Anti-tim3 antibody pharmaceutical composition and use thereof | |
| HK40069564B (en) | Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
| HK40059623A (en) | Pharmaceutical composition containing antibody against il-5 and use thereof | |
| HK40013346B (en) | Pd-l1 antibody pharmaceutical composition and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260105 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260105 |